Journal Mobile Options
Table of Contents
Vol. 139, No. 3, 2006
Issue release date: February 2006
Section title: Original Paper
Int Arch Allergy Immunol 2006;139:258–264
(DOI:10.1159/000091171)

Theophylline as ‘Add-on’ Therapy to Cetirizine in Patients with Chronic Idiopathic Urticaria

A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Kalogeromitros D.a · Kempuraj D.c · Katsarou-Katsari A.b · Makris M.a · Gregoriou S.b · Papaliodis D.c · Theoharides T.C.c-e
aDivision of Allergy, Attikon Hospital, University of Athens School of Medicine, and b1st Department of Dermatology and Venereology, A. Sygros Hospital, Athens, Greece; Departments of cPharmacology and Experimental Therapeutics, dBiochemistry and eInternal Medicine, Tufts University School of Medicine and Tufts-New England Medical Center, Boston, Mass., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/16/2005
Accepted: 10/31/2005
Published online: 2/22/2006
Issue release date: February 2006

Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Background: Chronic urticaria is a prevalent condition associated with substantial disability. Its pathogenesis is not clearly understood and is divided into autoimmune and chronic idiopathic urticaria (CIU). We investigated if the non-specific phosphodiesterase inhibitor theophylline could provide additional benefit to the histamine-1 receptor (H-1R) antagonist cetirizine in CIU. Methods: This was a double-blind, placebo-controlled, parallel study. Patients were randomized to receive either cetirizine and theophylline (200 mg twice daily; group A, 67 subjects) or cetirizine and placebo for 6 months (group B, 67 subjects). Group A patients took theophylline for 6 more months. Response was assessed by visual analog scale (VAS) and treatment effectiveness score (TES). Blood theophylline levels were also determined at visit t = 1 and t = 7. Results: The study was completed by 54 of the 67 patients (80.6%) in group A and 51 of the 67 patients (76.1%) in group B. The physician VAS values for group A were lower after t = 3, while the patient VAS values were decreased after t = 2. The physician and patient TES values in group A were statistically higher (p < 0.05) at all time points except for t = 1. At least 1 month of theophylline addition was necessary to obtain statistically significant benefit over cetirizine, and reducing theophylline by 50% during phase 2 did not alter this benefit. Pruritus values were reduced, but not statistically significant. Conclusions: Addition of theophylline to conventional H-1R antagonists was well tolerated without any adverse effects and provided considerable additional benefit in the management of CIU.

© 2006 S. Karger AG, Basel


  

Article Information

Received: August 16, 2005
Accepted after revision: October 31, 2005
Published online: January 30, 2006
Number of Print Pages : 7
Number of Figures : 5, Number of Tables : 1, Number of References : 38

  

Publication Details

International Archives of Allergy and Immunology

Vol. 139, No. 3, Year 2006 (Cover Date: February 2006)

Journal Editor: Valenta, R. (Vienna)
ISSN: 1018–2438 (print), 1423–0097 (Online)

For additional information: http://www.karger.com/IAA


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/16/2005
Accepted: 10/31/2005
Published online: 2/22/2006
Issue release date: February 2006

Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 1

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.